Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.
Petrioli R, Pascucci A, Conca R, Chiriacò G, Francini E, Bargagli G, Fiaschi AI, Manganelli A, De Rubertis G, Barbanti G, Ponchietti R, Francini G. Petrioli R, et al. Among authors: conca r. Br J Cancer. 2011 Feb 15;104(4):613-9. doi: 10.1038/bjc.2011.5. Epub 2011 Feb 1. Br J Cancer. 2011. PMID: 21285986 Free PMC article. Clinical Trial.
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
Petrioli R, Bargagli G, Lazzi S, Pascucci A, Francini E, Bellan C, Conca R, Martellucci I, Fiaschi AI, Lorenzi B, Francini G; Multidisciplinary Oncology Group in Gastrointestinal Tumors. Petrioli R, et al. Among authors: conca r. Anticancer Drugs. 2010 Mar;21(3):313-9. doi: 10.1097/CAD.0b013e328334d88a. Anticancer Drugs. 2010. PMID: 20016369 Clinical Trial.
Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel.
Francini F, Pascucci A, Francini E, Bargagli G, Conca R, Licchetta A, Roviello G, Martellucci I, Chiriacò G, Miano ST, Marzocca G, Manganelli A, Ponchietti R, Savelli V, Petrioli R. Francini F, et al. Among authors: conca r. Prostate Cancer. 2011;2011:258689. doi: 10.1155/2011/258689. Epub 2011 Aug 21. Prostate Cancer. 2011. PMID: 22096653 Free PMC article.
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
Petrioli R, Licchetta A, Roviello G, Pascucci A, Francini E, Bargagli G, Conca R, Miano ST, Marzocca G, Francini G; Multidisciplinary Oncology Group On Gastrointestinal Tumors. Petrioli R, et al. Among authors: conca r. Cancer Invest. 2012 Jan;30(1):65-71. doi: 10.3109/07357907.2011.629380. Cancer Invest. 2012. PMID: 22236191
Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
Francini F, Pascucci A, Bargagli G, Francini E, Conca R, Miano ST, Martellucci I, Migali C, Gotti G, Fiaschi AI, Cozzolino A, Petrioli R. Francini F, et al. Among authors: conca r. Int J Clin Oncol. 2011 Jun;16(3):264-9. doi: 10.1007/s10147-010-0179-x. Epub 2011 Jan 18. Int J Clin Oncol. 2011. PMID: 21240683 Clinical Trial.
Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.
Roviello G, Petrioli R, Nardone V, Rosellini P, Multari AG, Conca R, Aieta M. Roviello G, et al. Among authors: conca r. Medicine (Baltimore). 2018 May;97(20):e10745. doi: 10.1097/MD.0000000000010745. Medicine (Baltimore). 2018. PMID: 29768350 Free PMC article. Clinical Trial.
70 results